Foghorn Therapeutics Inc. (FHTX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
Foghorn Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 27,646 | $129,936.27 | $144,035.66 | $14,099.39 | 10.85% |
 Joseph Castro Nuveen LLC | 50,378 | $184,155.97 | $263,476.94 | $79,320.97 | 43.07% |
 Li Peng China Universal Asset Management Co. Ltd. | 10,396 | $49,139.18 | $56,138.4 | $6,999.22 | 14.24% |
 Kevin Kroskey True Wealth Design LLC | 20 | $90.27 | $109 | $18.73 | 20.75% |
| WPA Wealth Preservation Advisors LLC Wealth Preservation Advisors LLC | 13 | $62 | $67.6 | $5.6 | 9.03% |
Foghorn Therapeutics Inc. (FHTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Foghorn Therapeutics Inc. ever had a stock split?
Foghorn Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Adrian H. Gottschalk CEO | NASDAQ (NMS) Exchange | 344174107 CUSIP |
| US Country | 106 Employees | - Last Dividend | - Last Split | 23 Oct 2020 IPO Date |
Overview
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, United States. Established in 2015, the company focuses on the discovery and development of innovative medicines that target genetically determined dependencies within the chromatin regulatory system. By leveraging its proprietary Gene Traffic Control platform, Foghorn Therapeutics endeavors to identify, validate, and potentially drug targets that are integral to this system. The company has formed strategic collaborations with industry giants like Merck Sharp & Dohme Corp. and Eli Lilly and Company, aiming to advance its pipeline and bring novel oncology therapeutics to market.
Products and Services
Foghorn Therapeutics Inc. is currently developing a range of promising drugs and therapies targeting various forms of cancer, utilizing its novel approach towards understanding and manipulating the chromatin regulatory system:
- FHD-286: A small molecule inhibitor targeting the enzymatic activities of BRG1 and BRM. This drug is in phase I clinical trials for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. FHD-286 exemplifies Foghorn's approach to disrupting cancer cells' molecular machinery, aiming to provide a new therapeutic option for difficult-to-treat blood cancers.
- Therapies for Mutant Cancers: The company is also developing targeted therapies for a range of mutant cancers, such as Non-Small Cell Lung Cancer, bladder cancer, endometrial cancer, colorectal cancer, and melanoma. These efforts highlight Foghorn's commitment to addressing the genetic roots of cancer, providing targeted, potentially more effective treatments.
- Dependent Cancers: In addition to mutant cancers, Foghorn Therapeutics is focused on creating therapies for dependent cancers, including prostate cancer and diffuse large B-cell lymphoma. These therapies aim to exploit the dependencies of cancer cells on specific molecular pathways, thereby offering new hope to patients with these malignancies.
- Research Collaborations: Foghorn has entered into significant research collaborations and license agreements, notably with Merck Sharp & Dohme Corp. for the discovery and development of novel oncology therapeutics targeting a transcription factor, and with Eli Lilly and Company for the development of FHD-909, a selective ATPase inhibitor of BRM. These partnerships are pivotal to Foghorn's strategy, combining its proprietary platform and expertise with the resources and experience of established pharmaceutical companies to accelerate drug development and delivery.
